Final Overall Survival (Os) Analysis of Cou-Aa-302, a Randomized Phase 3 Study of Abiraterone Acetate (Aa) in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts) Without Prior Chemotherapy

Phase 3 ◽

Prior Chemotherapy ◽

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

The Journal of Urology ◽

10.1016/j.juro.2013.02.272 ◽

2013 ◽

Vol 189 (4S) ◽

Cited By ~ 1

Author(s):

Fred Saad ◽

Neal D Shore ◽

Hendrik Van Poppel ◽

Dana Rathkopf ◽

Matthew R. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Cancer Patients ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(12)70379-0 ◽

2012 ◽

Vol 13 (10) ◽

pp. 983-992 ◽

Cited By ~ 773

Author(s):

Karim Fizazi ◽

Howard I Scher ◽

Arturo Molina ◽

Christopher J Logothetis ◽

Kim N Chi ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

7000 ORAL Final Overall Survival (OS) Analysis of COU-AA-301, a Phase 3 Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Pretreated With Docetaxel

European Journal of Cancer ◽

10.1016/s0959-8049(11)71951-7 ◽

2011 ◽

Vol 47 ◽

pp. S483-S484 ◽

Cited By ~ 7

Author(s):

K. Fizazi ◽

H.I. Scher ◽

A. Molina ◽

C.J. Logothetis ◽

R.J. Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Phase 3 ◽

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(14)71205-7 ◽

2015 ◽

Vol 16 (2) ◽

pp. 152-160 ◽

Cited By ~ 642

Author(s):

Charles J Ryan ◽

Matthew R Smith ◽

Karim Fizazi ◽

Fred Saad ◽

Peter F A Mulders ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Castration Resistant ◽

Overall Survival Analysis

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

European Urology Supplements ◽

10.1016/s1569-9056(13)60589-8 ◽

2013 ◽

Vol 12 (1) ◽

pp. e97-e98

Author(s):

H. Van Poppel ◽

D. Rathkopf ◽

M.R. Smith ◽

J.S. De Bono ◽

C.J. Logothetis ◽

...

Keyword(s):

Prostate Cancer ◽

Interim Analysis ◽

Abiraterone Acetate ◽

Phase 3 ◽

Prior Chemotherapy ◽

Prognostic index model (PIM) for overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy treated with abiraterone acetate (AA).

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5047 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5047-5047 ◽

Cited By ~ 3

Author(s):

Charles J. Ryan ◽

Thian Kheoh ◽

Jinhui Li ◽

Arturo Molina ◽

Peter De Porre ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Prognostic Index ◽

Abiraterone Acetate ◽

Prior Chemotherapy ◽

Index Model ◽

Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer

Journal of Medical Economics ◽

10.3111/13696998.2016.1173042 ◽

2016 ◽

Vol 19 (8) ◽

pp. 777-784 ◽

Cited By ~ 14

Author(s):

Dominic Pilon ◽

Marykay Queener ◽

Patrick Lefebvre ◽

Lorie A. Ellis

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Median Overall Survival ◽

Abiraterone Acetate ◽

Era 223—A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and Prednisone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-Naïve Patients with Bone-Predominant Metastatic Castration-Resistant Prostate Cancer (Crpc)

Annals of Oncology ◽

10.1093/annonc/mdu336.50 ◽

2014 ◽

Vol 25 ◽

pp. iv278 ◽

Cited By ~ 1

Author(s):

M.R. Smith ◽

C. Parker ◽

B. Tombal ◽

K. Miller ◽

F. Saad ◽

...

Keyword(s):

Prostate Cancer ◽

Abiraterone Acetate ◽

Phase 3 ◽

Castration Resistant ◽

Radium 223

649P Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.908 ◽

2020 ◽

Vol 31 ◽

pp. S530

Author(s):

Z. Hu ◽

Z. Ye ◽

H. Zeng ◽

Y. Huang ◽

D. Ye ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Study ◽

Abiraterone Acetate ◽

Phase Iii ◽

Prior Chemotherapy ◽

Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT

Medicine ◽

10.1097/md.0000000000004308 ◽

2016 ◽

Vol 95 (31) ◽

pp. e4308 ◽

Cited By ~ 3

Author(s):

Jacob Farnebo ◽

Agnes Wadelius ◽

Per Sandström ◽

Sten Nilsson ◽

Hans Jacobsson ◽

...

Keyword(s):

Prostate Cancer ◽

Overall Survival ◽

Abiraterone Acetate ◽

Castration Resistant ◽

Pet Ct